{
    "clinical_study": {
        "@rank": "3230", 
        "arm_group": {
            "arm_group_label": "Ovation\u2122/Ovation Prime\u2122 Abdominal Stent Graft System", 
            "description": "Adult male and female patients will be consecutively screened for the study.  Eligible patients must meet all of the inclusion criteria and none of the exclusion criteria."
        }, 
        "brief_summary": {
            "textblock": "The Post-Approval Study (PAS) will evaluate the \"real world\" data on the Ovation\u2122/Ovation\n      Prime\u2122 Abdominal Stent Graft System along with the long-term data collected from the IDE\n      cohort to monitor the long-term safety and effectiveness of the device."
        }, 
        "brief_title": "Post-Approval Study of the Ovation\u2122/Ovation Prime\u2122 Abdominal Stent Graft System", 
        "completion_date": {
            "#text": "October 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Aortic Aneurysm, Abdominal", 
        "condition_browse": {
            "mesh_term": [
                "Aneurysm", 
                "Aortic Aneurysm", 
                "Aortic Aneurysm, Abdominal"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of the study is to demonstrate the long term safety and effectiveness of the\n      Ovation\u2122/Ovation Prime\u2122 Abdominal Stent Graft System for the endovascular treatment of\n      infrarenal abdominal aortic aneurysms in a post-approval environment.\n\n      The clinical objective of the study is to evaluate the long term safety and effectiveness of\n      the Ovation\u2122/Ovation Prime\u2122 Abdominal Stent Graft System assessed at 5 years through freedom\n      from Aneurysm-Related Mortality.\n\n      Additionally, this study will evaluate the physician training program for modifications\n      based on IDE and post-approval experience."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patient is > 18 years of age.\n\n          2. Patients who are male or non-pregnant female (females of child bearing potential must\n             have a negative pregnancy test prior to enrollment into the study).\n\n          3. Patient has signed an Institutional Review Board (IRB) approved Informed Consent\n             Form.\n\n          4. Patient is considered by the treating physician to be a candidate for elective open\n             surgical repair of the AAA (i.e., category I, II, or III per American Society of\n             Anesthesiology (ASA) classification; refer to Appendix III: ASA Classification\n             System).  ASA category IV patients may be enrolled provided their life expectancy is\n             greater than 1 year.\n\n          5. Patient has an infrarenal abdominal aortic aneurysm that meets at least one of the\n             following:\n\n               -  Abdominal aortic aneurysm >5.0 cm in diameter\n\n               -  Aneurysm has increased in size by 0.5 cm in last 6 months.\n\n               -  Maximum diameter of aneurysm exceeds 1.5 times the transverse dimension of an\n                  adjacent non-aneurysmal aortic segment\n\n          6. Patient has patent iliac or femoral arteries that allow endovascular access with the\n             TriVascular Ovation/Ovation Prime Abdominal Stent Graft System.\n\n          7. Patient has a suitable non-aneurysmal proximal aortic neck length of \u2265 7 mm inferior\n             to the most distal renal artery ostium.\n\n          8. Patient has a suitable non-aneurysmal distal iliac artery length (seal zone) of \u226510\n             mm. The resultant repair should preserve patency in at least one hypogastric artery.\n\n          9. Patient has a suitable non-aneurysmal proximal aortic neck luminal diameter between\n             16 and 30 mm.\n\n         10. Patient has suitable non-aneurysmal distal iliac luminal diameters between 8 and 20\n             mm.\n\n         11. Patient meets the following anatomic criteria:  the distance from the most distal\n             renal artery to most superior internal iliac artery measurement is at least 13 cm.\n\n         12. Patient has juxtarenal aortic neck angulation \u2264 60\u00ba if proximal neck is \u226510 mm and \u2264\n             45\u00ba if proximal neck is <10 mm. Patient must be willing to comply with all required\n             follow-up exams.\n\n         13. Patient must be willing to comply with all required follow-up exams.\n\n        Exclusion Criteria:\n\n          1. Patient has a dissecting aneurysm.\n\n          2. Patient has an acutely ruptured aneurysm.\n\n          3. Patient has an acute vascular injury.\n\n          4. Patient has a need for emergent surgery.\n\n          5. Patient has a known thoracic aortic aneurysm or dissection.\n\n          6. Patient has a mycotic aneurysm or has an active systemic infection.\n\n          7. Patient has unstable angina (defined as angina with a progressive increase in\n             symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina).\n\n          8. Patient has had a myocardial infarction (MI) and/or stroke (CVA) within the past 6\n             months.\n\n          9. Patient has a major surgical or interventional procedure planned \u226430 days of the AAA\n             repair.\n\n         10. Patient has history of connective tissue disease (e.g., Marfan's or Ehler's-Danlos\n             syndrome).\n\n         11. Patient has history of bleeding disorders or refuses blood transfusions.\n\n         12. Patient has dialysis dependent renal failure or baseline serum creatinine level >2.0\n             mg/dl\n\n         13. Patient has a known hypersensitivity or contraindication to anticoagulation or\n             contrast media that is not amenable to pre-treatment.\n\n         14. Patient has a known allergy or intolerance to polytetrafluoroethylene (PTFE),\n             PEG-based polymers, fluorinated ethylene propylene (FEP) or nitinol.\n\n         15. Patient has a body habitus that would inhibit X-ray visualization of the aorta\n\n         16. Patient has a limited life expectancy of less than 1 year\n\n         17. Patient is currently participating in an investigational device or drug clinical\n             trial.\n\n         18. Patient has other medical, social or psychological conditions that, in the opinion of\n             the investigator, preclude them from receiving the pre-treatment, required treatment,\n             and post-treatment procedures and evaluations."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "320 subjects enrolled with an estimated 192 evaluable subjects at the fifth year from the\n        following cohorts:\n\n          -  Available data from the 161 pivotal cohort subjects\n\n          -  All Continued Access subjects;\n\n          -  All subjects from the HDE PAS (reference H100008); and\n\n          -  A minimum of 59 subjects from de novo enrollment."
            }
        }, 
        "enrollment": {
            "#text": "320", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01980901", 
            "org_study_id": "771-0010"
        }, 
        "intervention": {
            "arm_group_label": "Ovation\u2122/Ovation Prime\u2122 Abdominal Stent Graft System", 
            "description": "Single occurence permanent implant of AAA device.", 
            "intervention_name": "Ovation\u2122/Ovation Prime\u2122 Abdominal Stent Graft System", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "AAA", 
        "lastchanged_date": "November 8, 2013", 
        "link": {
            "description": "TriVascular, Inc. Company Website", 
            "url": "http://www.TriVascular.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Peoria", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "61637"
                }, 
                "name": "OSF St. Francis Medical Center / HealthCare Midwest, LTD."
            }, 
            "investigator": {
                "last_name": "Syed Hussain, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Post-Market Approved (PMA) Post-Approval Study to Evaluate the Long-Term Safety and Effectiveness of the Ovation\u2122/Ovation Prime\u2122 Abdominal Stent Graft System", 
        "overall_contact": {
            "email": "soquinn@trivascular.com", 
            "last_name": "Shari O'Quinn", 
            "phone": "707-543-8807"
        }, 
        "overall_official": {
            "affiliation": "OSF St. Francis Medical Center / Proctor Hospital", 
            "last_name": "Syed Hussain, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint of the Ovation\u2122/Ovation Prime\u2122 Abdominal Stent Graft System study will be determined by evaluating freedom from aneurysm-related mortality at five (5) years. This will be compared to a target performance goal.", 
            "measure": "Freedom From Aneurysm-Related Mortality at 5 Years", 
            "safety_issue": "Yes", 
            "time_frame": "5 Years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01980901"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Serious Adverse Events (SAEs) within 30 days of the initial procedure and through 12 months and annually thereafter to 5 years\nAt 30 days and 12 months and annually thereafter to 5 years, the following rates will be reported:\nMortality (AAA-related and all-cause)\nDevice patency\nConversion to open surgical repair\nEndoleak\nAAA enlargement\nStent Graft Migration\nDevice integrity\nSecondary endovascular procedures\nAneurysm rupture", 
            "measure": "Composite Safety and Performance Endpoints", 
            "safety_issue": "Yes", 
            "time_frame": "1 Month & Annually 1 to 5 Years"
        }, 
        "source": "TriVascular, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "TriVascular, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}